BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34384565)

  • 1. Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
    Honda Y; Ozaki A; Iwaki M; Kobayashi T; Nogami A; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Yoneda M; Saito S; Nagashima Y; Nakajima A
    J Pharmacol Sci; 2021 Oct; 147(2):176-183. PubMed ID: 34384565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGL5213, a novel and potent intestinal SGLT1 inhibitor, suppresses intestinal glucose absorption and enhances plasma GLP-1 and GLP-2 secretion in rats.
    Io F; Gunji E; Koretsune H; Kato K; Sugisaki-Kitano M; Okumura-Kitajima L; Kimura K; Uchida S; Yamamoto K
    Eur J Pharmacol; 2019 Jun; 853():136-144. PubMed ID: 30878385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure.
    Ho HJ; Kikuchi K; Oikawa D; Watanabe S; Kanemitsu Y; Saigusa D; Kujirai R; Ikeda-Ohtsubo W; Ichijo M; Akiyama Y; Aoki Y; Mishima E; Ogata Y; Oikawa Y; Matsuhashi T; Toyohara T; Suzuki C; Suzuki T; Mano N; Kagawa Y; Owada Y; Katayama T; Nakayama T; Tomioka Y; Abe T
    Physiol Rep; 2021 Dec; 9(24):e15092. PubMed ID: 34921520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
    Kishida Y; Okubo H; Ohno H; Oki K; Yoneda M
    J Gastroenterol; 2017 Nov; 52(11):1180-1191. PubMed ID: 28349245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.
    Chiang H; Lee JC; Huang HC; Huang H; Liu HK; Huang C
    Br J Pharmacol; 2020 Jan; 177(2):239-253. PubMed ID: 31497874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Structure-Activity Relationship of C-Phenyl D-Glucitol (TP0454614) Derivatives as Selective Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitors.
    Kuroda S; Kobashi Y; Kawamura M; Kawabe K; Shiozawa F; Hamada M; Shimizu Y; Okumura-Kitajima L; Koretsune H; Kimura K; Yamamoto K; Kakinuma H
    Chem Pharm Bull (Tokyo); 2020; 68(7):635-652. PubMed ID: 32611999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
    Zhou ST; Cui W; Kong L; Yang X
    Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
    Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
    J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
    Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
    J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of calycosin against high-fat diet-induced nonalcoholic fatty liver disease in mice.
    Duan X; Meng Q; Wang C; Liu Z; Sun H; Huo X; Sun P; Ma X; Peng J; Liu K
    J Gastroenterol Hepatol; 2018 Feb; 33(2):533-542. PubMed ID: 28699662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment.
    Kuroda S; Kobashi Y; Oi T; Kawabe K; Shiozawa F; Okumura-Kitajima L; Sugisaki-Kitano M; Io F; Yamamoto K; Kakinuma H
    Bioorg Med Chem; 2019 Jan; 27(2):394-409. PubMed ID: 30579799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucosamine Improves Non-Alcoholic Fatty Liver Disease Induced by High-Fat and High-Sugar Diet through Regulating Intestinal Barrier Function, Liver Inflammation, and Lipid Metabolism.
    Li F; Zhang Z; Bai Y; Che Q; Cao H; Guo J; Su Z
    Molecules; 2023 Oct; 28(19):. PubMed ID: 37836761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
    Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
    Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Protective Effect of
    Zhao W; Song F; Hu D; Chen H; Zhai Q; Lu W; Zhao J; Zhang H; Chen W; Gu Z; Wang G
    Nutrients; 2020 Aug; 12(9):. PubMed ID: 32825154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SP-1154, a novel synthetic TGF-β inhibitor, alleviates obesity and hepatic steatosis in high-fat diet-induced mice.
    Pahk K; Lee SG; Joung C; Kim EO; Kwon HW; Kim DH; Hwang JI; Kim S; Kim WK
    Biomed Pharmacother; 2022 Jan; 145():112441. PubMed ID: 34813997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
    Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
    Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salicornia Extract Ameliorates Salt-Induced Aggravation of Nonalcoholic Fatty Liver Disease in Obese Mice Fed a High-Fat Diet.
    Kim JH; Suk S; Jang WJ; Lee CH; Kim JE; Park JK; Kweon MH; Kim JH; Lee KW
    J Food Sci; 2017 Jul; 82(7):1765-1774. PubMed ID: 28608557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.